全文获取类型
收费全文 | 1444篇 |
免费 | 118篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 86篇 |
妇产科学 | 15篇 |
基础医学 | 160篇 |
口腔科学 | 55篇 |
临床医学 | 192篇 |
内科学 | 282篇 |
皮肤病学 | 32篇 |
神经病学 | 74篇 |
特种医学 | 245篇 |
外科学 | 115篇 |
综合类 | 24篇 |
预防医学 | 68篇 |
眼科学 | 25篇 |
药学 | 93篇 |
中国医学 | 6篇 |
肿瘤学 | 89篇 |
出版年
2024年 | 3篇 |
2023年 | 12篇 |
2022年 | 4篇 |
2021年 | 25篇 |
2020年 | 16篇 |
2019年 | 23篇 |
2018年 | 37篇 |
2017年 | 18篇 |
2016年 | 29篇 |
2015年 | 32篇 |
2014年 | 40篇 |
2013年 | 47篇 |
2012年 | 47篇 |
2011年 | 50篇 |
2010年 | 50篇 |
2009年 | 71篇 |
2008年 | 51篇 |
2007年 | 41篇 |
2006年 | 44篇 |
2005年 | 34篇 |
2004年 | 29篇 |
2003年 | 41篇 |
2002年 | 32篇 |
2001年 | 28篇 |
2000年 | 35篇 |
1999年 | 31篇 |
1998年 | 54篇 |
1997年 | 57篇 |
1996年 | 73篇 |
1995年 | 53篇 |
1994年 | 45篇 |
1993年 | 51篇 |
1992年 | 29篇 |
1991年 | 16篇 |
1990年 | 26篇 |
1989年 | 38篇 |
1988年 | 34篇 |
1987年 | 36篇 |
1986年 | 36篇 |
1985年 | 27篇 |
1984年 | 18篇 |
1983年 | 10篇 |
1982年 | 22篇 |
1981年 | 14篇 |
1980年 | 8篇 |
1978年 | 4篇 |
1977年 | 13篇 |
1976年 | 12篇 |
1975年 | 13篇 |
1973年 | 3篇 |
排序方式: 共有1570条查询结果,搜索用时 468 毫秒
1.
Jose M. Morales Jose Angel Martinez-Flores Manuel Serrano Maria José Castro Francisco Javier Alfaro Florencio García Miguel Angel Martínez Amado Andrés Esther González Manuel Praga Estela Paz-Artal Antonio Serrano 《Journal of the American Society of Nephrology : JASN》2015,26(3):735-745
In the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti–β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation. 相似文献
2.
Abstract: The current study examined the extent to which mothers, fathers, teachers, and teenage friends influenced Latino adolescents’ academic motivation. Using path analysis, separate models were tested for 154 Latino boys and 156 Latina girls. Findings indicated that mothers’ and teachers’ academic support were positively related to adolescent girls’ academic motivation, and fathers’ and teachers’ academic support were positively related to adolescent boys’ academic motivation. The salience of teachers’ support, possible reasons for gender differences, and implications for future research are discussed. 相似文献
3.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
4.
5.
6.
7.
8.
9.
10.